- Home
- INCR vs ATRA Comparison
INCR vs ATRA Comparison
Compare INCR & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ATRA
- Stock Information
- Founded
- INCR 1994
- ATRA 2012
- Country
- INCR Israel
- ATRA United States
- Employees
- INCR N/A
- ATRA N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INCR Health Care
- ATRA Health Care
- Exchange
- INCR Nasdaq
- ATRA Nasdaq
- Market Cap
- INCR 65.3M
- ATRA 65.1M
- IPO Year
- INCR N/A
- ATRA 2014
- Fundamental
- Price
- INCR $1.46
- ATRA $10.46
- Analyst Decision
- INCR
- ATRA Hold
- Analyst Count
- INCR 0
- ATRA 5
- Target Price
- INCR N/A
- ATRA $26.88
- AVG Volume (30 Days)
- INCR 29.6K
- ATRA 76.3K
- Earning Date
- INCR 12-24-2024
- ATRA 11-12-2024
- Dividend Yield
- INCR N/A
- ATRA N/A
- EPS Growth
- INCR N/A
- ATRA N/A
- EPS
- INCR N/A
- ATRA N/A
- Revenue
- INCR $72,420,918.00
- ATRA $100,439,000.00
- Revenue This Year
- INCR N/A
- ATRA $1,368.80
- Revenue Next Year
- INCR $39.30
- ATRA N/A
- P/E Ratio
- INCR N/A
- ATRA N/A
- Revenue Growth
- INCR N/A
- ATRA 2111.34
- 52 Week Low
- INCR $1.17
- ATRA $6.50
- 52 Week High
- INCR $3.72
- ATRA $39.50
- Technical
- Relative Strength Index (RSI)
- INCR 52.10
- ATRA 42.51
- Support Level
- INCR $1.30
- ATRA $10.17
- Resistance Level
- INCR $1.47
- ATRA $13.64
- Average True Range (ATR)
- INCR 0.05
- ATRA 0.85
- MACD
- INCR 0.02
- ATRA -0.35
- Stochastic Oscillator
- INCR 88.83
- ATRA 8.81
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).